BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9587132)

  • 1. Mass screening for neuroblastoma targeting children age 14 months in Sapporo City: a preliminary report.
    Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Hirama T
    Cancer; 1998 May; 82(10):1973-7. PubMed ID: 9587132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mass screening of neuroblastoma in Sapporo City, Japan.
    Nishi M; Miyake H; Takeda T; Kikuchi Y; Hanai J; Yonemori H; Takasugi N
    Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):327-31. PubMed ID: 1456398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which cases are found and missed by neuroblastoma screening at 1 year? Results from the 1992 to 1995 study in three Federal States of Germany.
    Berthold F; Baillot A; Hero B; Schurr P; Nerenz A; Hunneman DH; Sander J
    J Clin Oncol; 1999 Apr; 17(4):1200. PubMed ID: 10561179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass screening for neuroblastoma in Miyagi Prefecture.
    Itano M; Morita S; Fujie H; Ohashi Y; Minegishi N; Minegishi M; Yamaguchi Y; Sato T; Tsuchiya S; Konno T
    Tohoku J Exp Med; 1992 Oct; 168(2):137-9. PubMed ID: 1306297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for neuroblastoma: a review of the evidence.
    Chamberlain J
    J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of mass screening for neuroblastoma in Sapporo, Japan.
    Takeda T; Nishi M; Shimada M; Nakadate H; Hatae Y; Naito H; Hanai J; Kawai T; Takasugi N
    Prog Clin Biol Res; 1991; 366():595-601. PubMed ID: 2068178
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of mass screening for neuroblastoma and the presumptive natural history of this tumor.
    Takeda T; Shimada M; Iizuka S; Takasugi N
    Prog Clin Biol Res; 1994; 385():383-8. PubMed ID: 7972235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass screening for neuroblastoma and mortality in birth cohorts.
    Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Takasugi N
    Int J Cancer; 1997 May; 71(4):552-5. PubMed ID: 9178807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vanillylmandelic acid, homovanillic acid, and catecholamines in urine of infants with neuroblastoma 6- to 11-month-old.
    Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J
    Jpn J Clin Oncol; 1986 Dec; 16(4):351-5. PubMed ID: 3795531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture, Japan.
    Yamamoto K; Hayashi Y; Hanada R; Kikuchi A; Ichikawa M; Tanimura M; Yoshioka S
    J Clin Oncol; 1995 Aug; 13(8):2033-8. PubMed ID: 7636545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cases of neuroblastoma missed by the mass screening programs.
    Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J; Kawai T
    Pediatr Res; 1989 Dec; 26(6):603-7. PubMed ID: 2602040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Japanese experience of screening.
    Takeda T; Hatae Y; Nakadate H; Nishi M; Hanai J; Sato Y; Takasugi N
    Med Pediatr Oncol; 1989; 17(5):368-72. PubMed ID: 2796852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based study of the usefulness of screening for neuroblastoma.
    Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
    Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for neuroblastoma at 3 weeks of age: methods and preliminary results from the Quebec Neuroblastoma Screening Project.
    Tuchman M; Lemieux B; Auray-Blais C; Robison LL; Giguere R; McCann MT; Woods WG
    Pediatrics; 1990 Nov; 86(5):765-73. PubMed ID: 2152340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stephen L. Gans overseas lecture. Mass screening for neuroblastoma in Japan: lessons learned and future directions.
    Suita S
    J Pediatr Surg; 2002 Jul; 37(7):949-54. PubMed ID: 12077747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure to detect dopaminergic neuroblastoma in a mass-screening system.
    Naito H; Takeda T; Hanai J
    J Pediatr Surg; 1995 Sep; 30(9):1317-8. PubMed ID: 8523234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec.
    Scriver CR; Gregory D; Bernstein M; Clow CL; Weisdorf T; Dougherty GE; Auray-Blais C; Giguère R; Lemieux B; Laberge C
    CMAJ; 1987 May; 136(9):952-6. PubMed ID: 3105859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for neuroblastoma in North America. 2-year results from the Quebec Project.
    Woods WG; Tuchman M; Bernstein ML; Leclerc JM; Brisson L; Look T; Brodeur GM; Shimada H; Hann HL; Robison LL
    Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):312-9. PubMed ID: 1456396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [5 years neuroblastoma screening in Austria: rate of participation, results and a comparison with other screening areas].
    Kerbl R; Urban CE; Ladenstein R; Schnellauf C; Sitzwohl C; Lackner H; Gleispach H; Fauler G; Ambros PF; Ambros IM; Rumpler S; Gadner H; Spuller E; Höfler G; Amann G; Kytir J; Mutz I
    Wien Klin Wochenschr; 1996; 108(13):398-403. PubMed ID: 8766424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass screening for neuroblastoma in infants.
    Wei M; Ye M; Dong K; Dong R
    Discov Med; 2020; 30(160):63-70. PubMed ID: 33382962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.